RxDoctor Payments Data

Kathleen Money, PA

Physician Assistant · Augusta, GANPI 1639840192

Payments from drug & device makers

$4,732in general payments, 2019–2025

Across 214 payments — averaging $22.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$679
  • Acorda Therapeutics, Inc$413
  • Acadia Pharmaceuticals Inc$385
  • Eisai Inc.$373
  • Kyowa Kirin, Inc.$328
  • Janssen Scientific Affairs, LLC$277
  • plus $2K from 27 others

What the payments were for

  • Food & beverage$4,726100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,732 in reported general payments places this provider in the 90th percentile of 3,581 physician assistant providers in Georgia.

See all physician assistant providers in Georgia

Medicare billing

Part B allowed, 2024
$36,744
Medicare patients
359
Services billed
483

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate15$135,086
IngrezzaValbenazine Tosylate16$130,460
NourianzIstradefylline30$111,415
AustedoDeutetrabenazine16$96,374
RytaryCarbidopa/Levodopa59$79,728
GocovriAmantadine Hcl26$70,797
MyrbetriqMirabegron73$52,874
Carbidopa-LevodopaCarbidopa/Levodopa314$15,784
Rasagiline Mesylate60$12,426
Entacapone60$12,349
Galantamine Hbr146$12,152
Rivastigmine47$11,657
Memantine Hcl303$10,034
Carbidopa-Levodopa-EntacaponeCarbidopa/Levodopa/Entacapone11$8,735
Donepezil Hcl573$6,886

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Acadia Pharmaceuticals IncNuplazid$385$135,08615 claims
Neurocrine Biosciences, Inc.Ingrezza$679$130,46016 claims
Kyowa Kirin, Inc.Nourianz$328$111,41530 claims
Teva Pharmaceuticals USA, Inc.Austedo$274$96,37416 claims
Amneal Pharmaceuticals LLCRytary$183$79,72859 claims
MDD US Operations, LLCGocovri$177$70,79726 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,581 physician assistant providers in Georgia.

Other physician assistant in Augusta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →